Serial No.: 10/008,535

IN THE CLAIMS:

Please amend the claims as follows:

1. (Currently amended) A compound according to Formula I:



wherein:

R_1, R_2, R_3 and R_4 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups;

R_5 is H, or, alkyl ~~or aryl~~;

R_6 is H, alkyl, ~~aryl,~~ or NR_7R_8, wherein R_7 and R_8 are each independently selected from the group consisting of H, and alkyl ~~and aryl~~; and

X is O, ~~S or NR_9, wherein R_9 is H or alkyl~~.

2. (Original) The compound according to Claim 1, wherein R_1 and R_2 are each an H.

3. (Original) The compound according to Claim 1, wherein R_1 and R_2 are each an H and R_3 and R_4 are each lower alkyls.

4. (Original) The compound according to Claim 1, wherein R_3 and R_4 are each a halide.

Serial No.: 10/008,535

5. (Original) The compound according to Claim 1, wherein R_3 and R_4 are each alkoxy.

6. (Original) The compound according to Claim 1, wherein R_3 and R_4 are each alkyl halides.

7. (Original) The compound according to Claim 1, wherein R_5 is an H, R_6 is a NR_7R_8, and R_7 and R_8 are each an H.

8. (Withdrawn) The compound according to Claim 1, wherein R_6 is a pyridyl.

9. (Withdrawn) The compound according to Claim 1, wherein R_6 is a substituted pyridyl.

10. (Withdrawn) The compound according to Claim 1, wherein R_6 is a quinolinyl.

11. (Currently amended) A pharmaceutical composition comprising a compound according to Formula I:



wherein:

R_1, R_2, R_3 and R_4 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups;

R_5 is H or, alkyl ~~or aryl~~;
R_6 is H, alkyl, ~~aryl,~~ or NR_7R_8, wherein R_7 and R_8 are each independently selected from the group consisting of H, and alkyl ~~and aryl~~; and
X is O, ~~S or NR_9, wherein R_9 is H or alkyl~~;
in a pharmaceutically acceptable carrier.

12. (Original) The pharmaceutical composition of Claim 11, wherein the composition is formulated for parenteral administration.

13. (Original) The pharmaceutical composition of Claim 11, wherein the composition is formulated for oral administration.

14. (Original) The pharmaceutical composition of Claim 11, wherein the composition is formulated for topical administration.

15. (Currently amended) A process for preparing a pharmaceutical composition comprising admixing ~~formulating~~ the compound of the formula (I) according to claim 1 and optionally a pharmaceutically utilizable carrier.

16. (Currently amended) A method of treating an microbial infection in a subject in need of such treatment, wherein the microbial infection is caused by a microorganism selected from the group consisting of *Mycobacterium tuberculosis*, *Trypanosoma* spp., *Candida albicans*, *Aspergillus* spp., *Cryptosporidium parvum*, *Giardia lamblia*, *Plasmodium* spp., *Pneumocystis carinii*, *Toxoplasma gondii*, *Fusarium solani*, and *Cryptococcus neoformans*, said method comprising administering to the subject a compound according to Formula I or a pharmaceutically acceptable salt thereof:

Serial No.: 10/008,535



wherein:

R_1, R_2, R_3 and R_4 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups;

R_5 is H or alkyl ~~or aryl~~;

R_6 is H, alkyl, ~~aryl,~~ or NR_7R_8, wherein R_7 and R_8 are each independently selected from the group consisting of H, and alkyl ~~and aryl~~; and

X is O, ~~S or NR_9, wherein R_9 is H or alkyl~~.

17. (Original) The method according to Claim 16, wherein the compound is administered parenterally.

18. (Original) The method according to Claim 16, wherein the compound is administered orally.

19. (Original) The method according to Claim 16, wherein the compound is administered topically.